TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9712245

Group type: COMPARATOR
Intervention: Intestinal sounds from healthy volunteers
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intestinal sounds from patients with intestinal obstruction
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bowel sounds from patients with peritonitis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Specialists in gastrointestinal medicine
Number of subjects: 12
Study: 8005843

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Caffeine withdrawal (placebo)
Number of subjects: 6
Study: 2916880

Group type: EXPERIMENTAL
Intervention: Food intake (meal)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fasting (control group)
Number of subjects: 36
Study: 31567605

Group type: EXPERIMENTAL
Intervention: Cable-driven gait trainer combined with conventional physiotherapy (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physiotherapy only (n = 20)
Number of subjects: 40
Study: 28681744

Group type: EXPERIMENTAL
Intervention: Maintained levodopa dose (Group 1, n = 66)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Reduced levodopa dose by 15-25% (Group 2, n = 41)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both groups after LCE administration
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both groups (safety population)
Number of subjects: 107
Study: 23893534

Group type: EXPERIMENTAL
Intervention: Physical activity (5 minutes of vigorous activity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary task (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical activity (Study 1)
Number of subjects: 0
Study: 24366725

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.5% (15 mg test dose + 50 mg)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: ADRB2 genotypes (Arg16Arg, Arg16Gly, Gly16Gly)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: ADRB2 genotypes (Gln27Gln, Gln27Glu, Glu27Glu)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: ADRB2 Glu27 allele
Number of subjects: 93
Study: 23031632

Group type: EXPERIMENTAL
Intervention: Silymarin cream (0.1) applied twice daily for 4 weeks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Silymarin cream (0.2) applied twice daily for 4 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo applied twice daily for 4 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 96
Study: 20415160

Group type: EXPERIMENTAL
Intervention: Self-controlled concurrent feedback
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Imposed concurrent feedback (yoked group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No concurrent feedback (control group)
Number of subjects: 15
Study: 17285318

Group type: EXPERIMENTAL
Intervention: 12-month Better Ageing structured group exercise programme
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Time spent sedentary (min/day)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Qualitative feedback from 27 research participants and 4 exercise leaders
Number of subjects: 176
Study: 15356071

Group type: EXPERIMENTAL
Intervention: Hormone therapy (transdermal estradiol 50 microg and micronized progesterone 100 mg/d)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11594636

Group type: EXPERIMENTAL
Intervention: Balance training in group, twice a week for eight weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study: 10909613

Group type: EXPERIMENTAL
Intervention: PUFA-enriched formula (Materna Premium)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular whey-predominant infant formula (Materna Plus)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 7734458

Group type: EXPERIMENTAL
Intervention: Buprenorphine gradual detoxification (36 days; N = 3)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Buprenorphine rapid detoxification (12 days; N = 5)
Number of subjects: 8
Study: 2675962

Group type: EXPERIMENTAL
Intervention: G + CS + CL
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: G + CL
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: G + CS + CO + CL
Number of subjects: 5

Group type: COMPARATOR
Intervention: G
Number of subjects: 5
Study: 31026331

Group type: EXPERIMENTAL
Intervention: Interdisciplinary care
Number of subjects: 129

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 129
Study: 28386739

Group type: EXPERIMENTAL
Intervention: Articaine 60 mg with fentanyl 10 µg (group AF10)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Articaine 60 mg with fentanyl 20 µg (group AF20)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Plain articaine 60 mg with saline (group AF0)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fentanyl 20 µg (group AF20)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 25361738

Group type: EXPERIMENTAL
Intervention: Heparin treatment in Han patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SERPINC1 gene sequencing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of SERPINC1 SNP frequency
Number of subjects: 0
Study: 23836249

Group type: EXPERIMENTAL
Intervention: Inhalation of 80 mg tobramycin twice daily for 12 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 44
Study: 21500267

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced cardiac magnetic resonance imaging with T(1) mapping and correction for patient-specific factors.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-correction T(1) values from normal subjects and type 1 diabetic patients.
Number of subjects: 0
Study: 19470834

Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 42
Study: 17229952

Group type: EXPERIMENTAL
Intervention: Early insertion of tympanostomy tubes
Number of subjects: 429

Group type: COMPARATOR
Intervention: Delayed insertion of tympanostomy tubes
Number of subjects: 429
Study: 15533901

Group type: EXPERIMENTAL
Intervention: Soy intervention (two daily servings of soy foods containing approximately 50 mg of isoflavones)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (maintained regular diet)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Soy intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study: 11533326

Group type: EXPERIMENTAL
Intervention: Single-dose ferrous sulfate drops (40 mg elemental iron once daily)
Number of subjects: 557

Group type: COMPARATOR
Intervention: 3-times-daily ferrous sulfate drops (40 mg elemental iron total per day)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Single-dose ferrous sulfate drops
Number of subjects: 557

Group type: COMPARATOR
Intervention: 3-times-daily ferrous sulfate drops
Number of subjects: 557
Study: 9190002

Group type: EXPERIMENTAL
Intervention: Amor criteria
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: ESSG criteria
Number of subjects: 157

Group type: COMPARATOR
Intervention: Comparison of Amor and ESSG criteria
Number of subjects: 157
Study: 2223330

Group type: EXPERIMENTAL
Intervention: Alfentanil 50 micrograms kg‐1 followed by an infusion of 50 micrograms kg‐1 h‐1 and propofol infusion
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Clonidine 0.6 mg added to premedication
Number of subjects: 51
Study: 6989245

Group type: EXPERIMENTAL
Intervention: Multidose intravenous sodium cephalothin
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Single-dose intravenous sodium cephalothin
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Single-dose oral metronidazole
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control groups from previous studies
Number of subjects: 79
Study: 31407871

Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil orally once daily for 12 weeks
Number of subjects: 53
Study: 28583031

Group type: EXPERIMENTAL
Intervention: Bortezomib dose intensity ≥4.6 mg/m2/cycle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib dose intensity <4.6 mg/m2/cycle
Number of subjects: 0
Study: 29280434

Group type: EXPERIMENTAL
Intervention: Ablation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Active Surveillance
Number of subjects: 6
Study: 25456560

Group type: EXPERIMENTAL
Intervention: Single ascending doses of 3.7 to 55.7 mg of samidorphan
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Multiple ascending doses of 10 or 20 mg of samidorphan for 7 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 46
Study: 24268098

Group type: EXPERIMENTAL
Intervention: HARP
Number of subjects: 40

Group type: COMPARATOR
Intervention: LDN
Number of subjects: 40
Study: 21902546

Group type: EXPERIMENTAL
Intervention: Intraluminal brachytherapy (ILBT) using ¹²⁵I seed strands
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group with only biliary stent insertion
Number of subjects: 34
Study: 19755964

Group type: EXPERIMENTAL
Intervention: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group A (immunosuppressed patients)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group B (non-immunosuppressed patients)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group C (healthy controls)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group A
Number of subjects: 64
Study: 18616088

Group type: EXPERIMENTAL
Intervention: Fixed combination of 20 mg cinnarizine and 40 mg dimenhydrinate (one tablet three times daily) for 4 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: COMPARATOR
Intervention: Betahistine (12 mg betahistine dimesylate, one tablet three times daily) for 4 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fixed combination of 20 mg cinnarizine and 40 mg dimenhydrinate
Number of subjects: 37
Study: 16139582

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation plus treatment as usual (VNS+TAU)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 329
Study: 11846847

Group type: EXPERIMENTAL
Intervention: Emdogain
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (propylene glycol alginate)
Number of subjects: 36
Study: 9885792

Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guanfacine 29 micrograms/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine 2 and 5 micrograms/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine 5 and Guanfacine 29 micrograms/kg
Number of subjects: 0
Study: 8771612

Group type: EXPERIMENTAL
Intervention: Early sleep deprivation (sleep 03:00-07:00 h)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Late sleep deprivation (sleep 21:00-01:00 h)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal volunteers (control group)
Number of subjects: 41
Study: 1466871

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 8)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (n = 6)
Number of subjects: 14
Study: 3971683

Group type: EXPERIMENTAL
Intervention: Oral narcotic analgesics plus ibuprofen 400 mg four times daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral narcotic analgesics alone (placebo)
Number of subjects: 10
Study: 30709627

Group type: EXPERIMENTAL
Intervention: Patient-information video
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 200
Study: 29741912

Group type: EXPERIMENTAL
Intervention: Standardized capsules of Stachys lavandulifolia
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 29
Study: 26903580

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy (LG) with D2 lymphadenectomy
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Open gastrectomy (OG) with D2 lymphadenectomy
Number of subjects: 1056
Study: 25212696

Group type: EXPERIMENTAL
Intervention: MI-PST intervention to reduce harmful/hazardous alcohol use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Equal-attention wellness intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 21450577

Group type: EXPERIMENTAL
Intervention: Treadmill exercise testing
Number of subjects: 55

Group type: COMPARATOR
Intervention: Bicycle exercise testing
Number of subjects: 55
Study: 20448177

Group type: EXPERIMENTAL
Intervention: Hand washing (physical cleansing)
Number of subjects: 0
Study: 17647055

Group type: EXPERIMENTAL
Intervention: 3 g of chili powder along with antibiotics and analgesics
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antibiotics and analgesics alone
Number of subjects: 60
Study: 15999594

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy alone or in combination with hormone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard hormone therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone therapy and chemotherapy
Number of subjects: 0
Study: 11920978

Group type: EXPERIMENTAL
Intervention: CBT with exercise and maintenance
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: CBT with exercise
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: CBT with maintenance
Number of subjects: 114

Group type: COMPARATOR
Intervention: CBT only
Number of subjects: 114
Study: 9859533

Group type: EXPERIMENTAL
Intervention: Cefoxitin 3 x 1 g (14 subjects)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Cefotetan 2 x 1 g (43 subjects)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Cefalotin 3 x 2 g for 24 hours (27 subjects)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Cefalotin 3 x 2 g for 72 hours (41 subjects)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (30 subjects) without prophylaxis
Number of subjects: 155
Study: 7881264

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) mouthwash, 5 ml solution at 10% in olive oil, used for five minutes, three times a day for eight weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetonide of triamcinolone 01% in aqueous solution (control group).
Number of subjects: 0
Study: 1983349

Group type: EXPERIMENTAL
Intervention: Intravenous pentagastrin (0.6 microgram.kg/h) with placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous pentagastrin (0.6 microgram.kg/h) with ranitidine 300 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 12
Study: 530855

Group type: EXPERIMENTAL
Intervention: One-step treatment
Number of subjects: 204

Group type: COMPARATOR
Intervention: Planned interval treatment
Number of subjects: 204
Study: 30506696

Group type: EXPERIMENTAL
Intervention: Weight management program
Number of subjects: 425

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 425
Study: 27677220

Group type: EXPERIMENTAL
Intervention: Cerec infinident
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lava
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: iTero
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cerec inLab
Number of subjects: 10
Study: 25847678

Group type: EXPERIMENTAL
Intervention: Thio-Ben plus cryotherapy (TC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Glucantime plus cryotherapy (GC)
Number of subjects: 64
Study: 24368466

Group type: EXPERIMENTAL
Intervention: Diflunisal, 250 mg twice daily for 2 years
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo, twice daily for 2 years
Number of subjects: 130
Study: 21807773

Group type: EXPERIMENTAL
Intervention: Intravenous slow 5 IU oxytocin bolus over 1 minute and additional 40 IU oxytocin infusion in 500 mL of 0.9% saline solution over 4 hours (bolus and infusion)
Number of subjects: 2069

Group type: COMPARATOR
Intervention: 5 IU oxytocin bolus over 1 minute and 500 mL of 0.9% saline solution over 4 hours (placebo infusion) (bolus only)
Number of subjects: 2069
Study: 19102515

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 or 40 mg/day
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 or 40 mg/day with or without hydrochlorothiazide
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 507
Study: 16883966

Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation (0.625 mg/day)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: B vitamin compound supplementation (riboflavin 0.625 mg/day, thiamin 0.512 mg/day, nicotinic acid 0.365 mg/day, folic acid 0.13 mg/day)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Supplemental control group
Number of subjects: 101
Study: 15219499

Group type: EXPERIMENTAL
Intervention: Hypertensive group
Number of subjects: 456

Group type: COMPARATOR
Intervention: Nonhypertensive group
Number of subjects: 456
Study: 11725851

Group type: EXPERIMENTAL
Intervention: Nociceptive Trigeminal Inhibition Tension Suppression System
Number of subjects: 0
Study: 9469527

Group type: EXPERIMENTAL
Intervention: Oral sustained-release morphine
Number of subjects: 6
Study: 8184813

Group type: EXPERIMENTAL
Intervention: Lisinopril 5 mg (target 20 mg)/day (n = 20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 41
Study: 3309233

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (30 to 40 mg/kg/24 hr)
Number of subjects: 21
Study: 31964660

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy with standard podiatry care over 24 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: None (Substudy 1)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 78
Study: 29535130

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus 9 weeks of trastuzumab
Number of subjects: 232

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Combined analysis of both treatment arms
Number of subjects: 232
Study: 27871584

Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation (SV)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 39
Study: 24157957

Group type: EXPERIMENTAL
Intervention: Aleglitazar plus single-dose warfarin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 12
Study: 23021692

Group type: EXPERIMENTAL
Intervention: Sacrospinous fixation (SSF)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Total mesh (Prolift; Gynecare/Ethicon)
Number of subjects: 168
Study: 20418072

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day for 3 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 15
Study: 18714059

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg) plus vitamin B(12) (0.4 mg)
Number of subjects: 3096

Group type: EXPERIMENTAL
Intervention: Vitamin B(6) (40 mg)
Number of subjects: 3096

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3096
Study: 15817716

Group type: EXPERIMENTAL
Intervention: Initial bout of plyometric exercise in men
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Initial bout of plyometric exercise in boys
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Second bout of plyometric exercise
Number of subjects: 20
Study: 12421060

Group type: EXPERIMENTAL
Intervention: Baseball batting simulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitch speed variance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotation cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: History of previous pitches and pitch count
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expertise
Number of subjects: 0
Study: 10339732

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - Beclomethasone dipropionate (BDP) 0.4 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no ICS)
Number of subjects: 48
Study: 8984131

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 193

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 193
Study: 2117204

Group type: EXPERIMENTAL
Intervention: Curosurf (200 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High ventilator pressure and oxygen requirements
Number of subjects: 0
Study: 323793

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza A vaccine administered intranasally
Number of subjects: 46

Group type: COMPARATOR
Intervention: Killed subunit vaccine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza A vaccine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza A vaccine and Killed subunit vaccine
Number of subjects: 46
Study: 31625653

Group type: EXPERIMENTAL
Intervention: Adapted antibiotic stewardship intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Public commitment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postimplementation survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preimplementation phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation outcome metrics
Number of subjects: 0
Study: 30879569

Group type: EXPERIMENTAL
Intervention: Marine n-3 PUFAs (2.6 g daily)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 132
Study: 28588101

Group type: EXPERIMENTAL
Intervention: 1 egg per day for 6 months
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 163
Study: 24840781

Group type: EXPERIMENTAL
Intervention: Ferric citrate 6 g/day
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Ferric citrate 4 g/day
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166